Calidi Biotherapeutics, Inc., announced that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s Phase 1 clinical trial treating brain tumor patients with an engineered oncolytic adenovirus delivered by neural stem cells.
[Calidi Biotherapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.
